IL5
ENSG00000113525
Target class
Secreted protein
Chromosome
5
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- IL5
- Gene name
- Interleukin 5
- Gene symbol
- IL5
- Protein name
- Interleukin-5 (IL-5) (B-cell differentiation factor I) (Eosinophil differentiation factor) (T-cell replacing factor) (TRF)
- IL-5
- EDF
- TRF
- Gene biotype
- Protein coding
- Gene family
- Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 6.72
- Tissue specificity (Gini)
- 0.775
- Tissue specificity (tau)
- 0.99
- KEGG gene identifiers
- hsa:3567
- Protein interaction confidence
- 0.827698
- Protein interaction partners
- 96
- R-HSA-512988
- R-HSA-5673001
- R-HSA-912526
- R-HSA-9976102
- End position
- 132556838
- Start position
- 132541445
- Chromosome
- 5
- Strand
- Reverse
- Secreted .
Publication evidence
- PubMed 2653458
- Tissue specificity (tau)
- 0.990089
- Expression inequality (Gini)
- 0.774688
Expression in transcripts per million
- Testis
- 6.72
- Brain - Cerebellum
- 0.18
- Ovary
- 0.18
- Cervix - Endocervix
- 0.17
- Uterus
- 0.17
Expression in transcripts per million
- Testis6.72
- Brain - Cerebellum0.18
- Ovary0.18
- Cervix - Endocervix0.17
- Uterus0.17
- Artery - Aorta0.14
- Pituitary0.14
- Brain - Cerebellar Hemisphere0.13
- Nerve - Tibial0.12
- Artery - Tibial0.11
- Artery - Coronary0.11
- Esophagus - Gastroesophageal Junction0.11
- Fallopian Tube0.1
- Cervix - Ectocervix0.1
- Colon - Sigmoid0.1
- Vagina0.09
- Brain - Spinal cord (cervical c-1)0.09
- Thyroid0.08
- Esophagus - Muscularis0.08
- Brain - Hypothalamus0.08
- Small Intestine - Terminal Ileum0.07
- Bladder0.07
- Brain - Caudate (basal ganglia)0.07
- Cells - EBV-transformed lymphocytes0.06
- Lung0.06
And 29 more, listed on the interactive page.
- GO:0006954
- GO:0007259
- GO:0038043
- GO:0046427
- GO:0071803
Cellular components
- GO:0005576
- GO:0005125
- GO:0005137
- GO:0005515
Related records
Trials (144)
- A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
- A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
- A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
- A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
- A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
- A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
- A Study of Depemokimab in Participants of 6 to 11 Years of Age
- A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
- A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
- A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
- A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
- A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
- A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
- A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
- A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
- A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
Drugs (3)
- Depemokimab Interleukin-5 inhibitor
- Mepolizumab Interleukin-5 inhibitor
- Reslizumab Interleukin-5 inhibitor